CAS NO: | 870093-23-5 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Talarozole R enantiomer is a potent and selective inhibitor ofcytochrome P45026-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis and acne. Target:CYP26in vitro: Talarozole R enantiomer treatment increased the mRNA expression of CRABP2, KRT4, CYP26A1 and CYP26B1 dose dependently, and decreased theexpression of KRT2 and IL-1alpha compared with vehicle-treated skin. No mRNA change in retinol-metabolizing enzymes was obtained. There was no induction of epidermal thickness or overt skin inflammation in talarozole-treated skin. Immunofluorescence analysis confirmed an upregulation of KRT4 protein, but no upregulation of CYP26A1 and CYP26B1 expression was detected [1] [2]. in vivo: Talarozole R enantiomer slightly diffused into the skin only when dissolved in propylene glycol, isopropyl myristate or ethanol. Although only 0.1% of the dose applied was found in the skin itself after 12-24 h, this was sufficient to achieve local concentrations well above the half-maximal inhibitory concentration value for talarozole. The distribution of talarozole within the skin was investigated: 80% was located in the epidermis, while the remaining 20% was found in the dermis [3]. | ||||||||||||||||
分子量 | 377.51 | ||||||||||||||||
Formula | C21H23N5S | ||||||||||||||||
CAS 号 | 870093-23-5 | ||||||||||||||||
中文名称 | (R)-他拉罗唑 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 51 mg/mL(135.10 mM) *"≥" means soluble, but saturation unknown. 配制储备液
|